DTC
Deep Track Capital Portfolio holdings
AUM
$3.58B
1-Year Est. Return
45.33%
1 Year Est. Return
+45.33%
AUM
$3.58B
AUM Growth
+$473M
(+15%)
Holding
76
Top Buys
| 1 | +$74.3M | |
| 2 | +$54.7M | |
| 3 | +$52.9M | |
| 4 |
Akero Therapeutics
AKRO
|
+$45.5M |
| 5 |
Cytokinetics
CYTK
|
+$35.7M |
Top Sells
| 1 | +$176M | |
| 2 | +$102M | |
| 3 | +$70.9M | |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$49.1M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$41.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Guardant Health
GH
$14.1B
| $260M | 7.24% |
4,154,086
-95,914
|
|
||
2
Ionis Pharmaceuticals
IONS
$13.4B
| $249M | 6.95% |
3,808,144
-1,083,400
|
|
||
|
3
Cytokinetics
CYTK
$8.33B
| $236M | 6.6% |
4,300,000
+650,000
|
|
||
|
4
Akero Therapeutics
AKRO
$4.47B
| $190M | 5.3% |
4,000,978
+958,380
|
|
||
5
Apellis Pharmaceuticals
APLS
$2.69B
| $181M | 5.05% |
8,000,382
+1,000,382
|
|
||
6
Tarsus Pharmaceuticals
TARS
$3.39B
| $178M | 4.98% |
3,000,000
+1,250,000
|
|
||
7
Immunovant
IMVT
$4.23B
| $157M | 4.38% |
9,728,845
+228,845
|
|
||
8
Dynavax Technologies
DVAX
$1.34B
| $156M | 4.36% |
15,726,349
-2,065,137
|
|
||
9
Ocular Therapeutix
OCUL
$2.59B
| $139M | 3.89% |
11,932,137
-2,362,283
|
|
||
|
ETNB
10
DELISTED
89bio
ETNB
| $138M | 3.84% |
9,356,171
-143,829
|
|
||
11
Structure Therapeutics
GPCR
$2.17B
| $118M | 3.29% |
4,215,811
-918,106
|
|
||
12
Viridian Therapeutics
VRDN
$3.05B
| $116M | 3.24% |
5,380,449
|
|
||
13
Protagonist Therapeutics
PTGX
$5.63B
| $114M | 3.18% |
1,715,691
-1,530,208
|
|
||
14
Axsome Therapeutics
AXSM
$7.64B
| $109M | 3.05% |
900,000
+98,629
|
|
||
15
Vaxcyte
PCVX
$6.49B
| $108M | 3.02% |
3,000,000
+850,000
|
|
||
|
MAZE
16
Maze Therapeutics
MAZE
$1.82B
| $102M | 2.86% |
3,948,910
|
|
||
17
Immunocore
IMCR
$2B
| $65.4M | 1.83% |
1,800,000
|
|
||
18
BridgeBio Pharma
BBIO
$13.9B
| $62.3M | 1.74% |
1,200,000
+300,000
|
|
||
19
Geron
GERN
$753M
| $56.3M | 1.57% |
41,096,522
-1,903,478
|
|
||
20
Terns Pharmaceuticals
TERN
$2.53B
| $56.3M | 1.57% |
7,495,000
|
|
||
21
Nurix Therapeutics
NRIX
$1.79B
| $56M | 1.56% |
6,057,024
-7,886
|
|
||
|
MBX
22
MBX Biosciences
MBX
$1.55B
| $55.1M | 1.54% |
3,150,000
+961,408
|
|
||
23
Exact Sciences
EXAS
$19.2B
| $54.7M | 1.53% |
+1,000,000
|
|
||
|
LBRX
24
LB Pharmaceuticals
LBRX
$450M
| $52.9M | 1.48% |
+3,352,804
|
|
||
25
Celldex Therapeutics
CLDX
$1.8B
| $51.7M | 1.44% |
2,000,000
|
|